Pulmonary vascular diseases
Respiratory critical care
Oral presentation
All about pulmonary arterial hypertension
Aims : This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
Methods :
Cell and molecular biology, General respiratory patient care, Transplantation, Physiology, Pulmonary function testing
09:30
Introduction
1
OA139
09:35
PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)
M. Hoeper(Hannover, Germany)
COI
2
09:40
Risk stratification in patients with pulmonary arterial hypertension (PAH) and candidates for lung or heart-lung transplantation
H. Vicaire(Paris, France)
COI
3
09:45
Lack of agreement between the exercise variables to assess the risk in PAH.
V. Mora Cuesta(Santander (Cantabria), Spain)
COI
4
09:50
Feasibility and Validation Testing of the Walk.Talk.Track. (WTT) App for Remote Monitoring of the Six Minute Walk Test (6MWT) in Pulmonary Arterial Hypertension (PAH).
V. Glinskii(Stanford, United States)
COI
5
09:55
Dehydroepiandrosterone and GDF-15 for follow-up of patients with pulmonary arterial hypertension
V. Foris(Graz, Austria)
COI
6
10:00
Pulmonary arterial hypertension in Adult-Onset Still’s Disease
A. Boucly(London, United Kingdom)
COI
7
10:05
Association between Leflunomide and Pulmonary Hypertension
T. Lacoste-Palasset(Le Kremlin-Bicetre, France)
COI
8
10:10
Pregnancy in pulmonary arterial hypertension: mid-term outcomes of mothers and offspring
K. Olsson(Hannover, Germany)
COI
9
10:15
Favorable pregnancy outcomes in women with predominantly mild pulmonary arterial hypertension
S. Saxer(Zürich, Switzerland)
COI
10
10:20
Late Breaking Abstract - Convergence of clinical and computational phenotypes for rare variant association study (RVAS) in pulmonary arterial hypertension
E. ŚWIETLIK(CAMBRIDGE, United Kingdom)
COI
11
10:25
Discussion
12
OA150
. . .
